A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Trial Profile

A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs TAS 115 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 12 Aug 2016 Planned number of patients changed from 67 to 90.
    • 12 Aug 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2018.
    • 02 Jun 2015 Interim results in 18 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top